- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02397954
A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
A Phase 2a Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment experienced (Prior treatment with anti-VEGF monotherapy of ≥8 injections in the previous twelve (12) months) subjects of either gender aged 50 years or above with a diagnosis of IPCV, will receive 3 monthly (Q4W) intravitreal injections of Zimura™ (1 mg/eye) in combination with anti-VEGF therapy (Avastin® 1.25 mg/eye or Lucentis® 0.5 mg/eye or Eylea® 2 mg/eye).
Safety endpoints include visual acuity loss (proportion of subjects with >15 letter loss at Month 3), ophthalmic adverse events (AEs), systemic adverse events (AEs), change in total retinal thickness (SD-OCT) at Month 3, regression and/or elimination of polyps at Month 3 compared to screening as measured by indocyanine green angiography (ICGA), and laboratory values.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85014
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects of either gender aged ≥ 50 years
- Diagnosis of IPCV
- Treatment-experienced defined as prior treatment with anti-VEGF mono therapy of ≥ 8 injections in the previous twelve (12) months
Exclusion Criteria:
- Any intraocular surgery or thermal laser within three (3) months of trial entry
- Any prior thermal laser in the macular region, regardless of indication
- Any ocular or periocular infection in the twelve (12) weeks prior to entry
- History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant
- Previous therapeutic radiation in the region of the study eye
- A diagnosis of diabetic retinopathy (presence of microaneurysms or any vasculopathy and/or leakage from retinal vasculature in a subject with diabetes mellitus)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zimura + Anti-VEGF
Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
|
Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With >15 ETDRS Letter Loss at Month 3
Time Frame: 3 Months
|
Number of participants with >15 ETDRS letter loss (with calculated percentage)
|
3 Months
|
Number of Participants With Ophthalmic Adverse Events
Time Frame: 3 months
|
Number of Participants with Ophthalmic Adverse Events (with calculated percentage)
|
3 months
|
Number of Participants With Systemic Adverse Events
Time Frame: 3 months
|
Number of Participants with Systemic Adverse Events (with calculated percentage)
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3
Time Frame: Baseline and Month 3
|
Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT
|
Baseline and Month 3
|
Regression and/or Elimination of Polyps at Month 3
Time Frame: Baseline and Month 3
|
Regression and/or Elimination of Polyps from baseline to Month 3
|
Baseline and Month 3
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Eye Diseases
- Uveal Diseases
- Choroid Diseases
- Metaplasia
- Neovascularization, Pathologic
- Choroidal Neovascularization
- Vascular Diseases
- Polypoidal Choroidal Vasculopathy
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- OPH2002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Polypoidal Choroidal Vasculopathy
-
Ophthotech CorporationWithdrawnIdiopathic Polypoidal Choroidal VasculopathyUnited States
-
Peking Union Medical College HospitalBayerRecruitingPolypoidal Choroidal VasculopathyChina
-
Federico II UniversityCompleted
-
Sun Yat-sen UniversityCompletedPolypoidal Choroidal VasculopathyChina
-
Nihon UniversityCompletedPolypoidal Choroidal VasculopathyJapan
-
Chiang Mai UniversityRecruitingPolypoidal Choroidal VasculopathyThailand
-
Mateon TherapeuticsCompletedPolypoidal Choroidal VasculopathyUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Seoul St. Mary's HospitalUnknownPolypoidal Choroidal VasculopathyKorea, Republic of
-
Xiaodong SunShanghai Zhongshan Hospital; Eye & ENT Hospital of Fudan UniversityUnknownPolypoidal Choroidal VasculopathyChina
-
Association for Innovation and Biomedical Research...European Vision Institute Clinical Research NetworkCompletedPolypoidal Choroidal VasculopathyPortugal, Spain
Clinical Trials on Zimura
-
IVERIC bio, Inc.Active, not recruitingStargardt Disease 1Italy, United States, Israel, United Kingdom, Germany, Spain, Hungary, France
-
IVERIC bio, Inc.CompletedMacular Degeneration | Geographic AtrophyUnited States, Spain, France, Germany, Austria, Belgium, Israel, Poland, Canada, Italy, Estonia, Australia, United Kingdom, Hungary, Argentina, Brazil, Colombia, Croatia, Czechia, Latvia
-
IVERIC bio, Inc.Active, not recruitingMacular Degeneration | Geographic AtrophyUnited States, Latvia, France, Germany, Spain, Hungary, Canada, Israel, Argentina, Czechia, Colombia, Croatia, Italy
-
IVERIC bio, Inc.CompletedMacular Degeneration | Geographic AtrophyUnited States, Israel, Estonia, Hungary, Latvia, Czechia, Croatia
-
Ophthotech CorporationCompletedWet Age-related Macular DegenerationUnited States, Hungary, Latvia
-
Ophthotech CorporationWithdrawnIdiopathic Polypoidal Choroidal VasculopathyUnited States
-
IVERIC bio, Inc.Terminated